433 related articles for article (PubMed ID: 36213111)
41. Role of CD47 in tumor immunity: a potential target for combination therapy.
Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
[TBL] [Abstract][Full Text] [Related]
42. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
43. A comprehensive pan-cancer analysis of CDH5 in immunological response.
Li Y; Wu Q; Lv J; Gu J
Front Immunol; 2023; 14():1239875. PubMed ID: 37809080
[TBL] [Abstract][Full Text] [Related]
44. Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.
Bai Y; Li L; Li J; Lu X
Heliyon; 2024 May; 10(9):e30727. PubMed ID: 38774095
[TBL] [Abstract][Full Text] [Related]
45. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
Front Oncol; 2020; 10():585961. PubMed ID: 33552963
[TBL] [Abstract][Full Text] [Related]
47. Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms.
Wang Y; Liu S; Chen Y; Zhu B; Xing Q
World J Oncol; 2022 Feb; 13(1):27-37. PubMed ID: 35317332
[TBL] [Abstract][Full Text] [Related]
48. Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
Li H; Sun X; Zhao Y; Zhang C; Jiang K; Ren J; Xing L; He M
BMC Cancer; 2023 Jun; 23(1):528. PubMed ID: 37296415
[TBL] [Abstract][Full Text] [Related]
49. Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis.
Lin T; Zhang Y; Lin Z; Peng L
Front Genet; 2021; 12():764245. PubMed ID: 34777483
[No Abstract] [Full Text] [Related]
50. Allograft inflammatory factor 1 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer.
Liu X; Zhang D; Hu J; Xu S; Xu C; Shen Y
Aging (Albany NY); 2023 Apr; 15(7):2582-2609. PubMed ID: 37014322
[TBL] [Abstract][Full Text] [Related]
51. Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.
Ren Q; Zhu P; Zhang H; Ye T; Liu D; Gong Z; Xia X
Cancer Cell Int; 2020; 20():92. PubMed ID: 32226313
[TBL] [Abstract][Full Text] [Related]
52. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
Zheng D; Long S; Xi M
Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
[TBL] [Abstract][Full Text] [Related]
53. Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.
Li X; Zhai S; Zhang J; Zhang D; Wang S; Wang L; Yu J
Front Oncol; 2021; 11():698465. PubMed ID: 34195096
[TBL] [Abstract][Full Text] [Related]
54. The prognostic value and immunological role of CD44 in pan-cancer study.
Chen S; Zhang S; Chen S; Ma F
Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
[TBL] [Abstract][Full Text] [Related]
55. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
56. Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.
Zhao H; Xie R; Zhang C; Lu G; Kong H
Front Genet; 2022; 13():989460. PubMed ID: 36159971
[No Abstract] [Full Text] [Related]
57. Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Patients With Colon Cancer and to Assist in Immunotherapy.
Xu B; Peng Z; Yan G; Wang N; Chen M; Yao X; Sun M; An Y
Front Genet; 2021; 12():726387. PubMed ID: 34552622
[TBL] [Abstract][Full Text] [Related]
58. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
59. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
60. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
